Jeff Yass Susquehanna International Group
Jeff Yass is a co-founder of Susquehanna International Group (SIG), a major global trading and market-making firm. SIG is known for options expertise, quantitative trading, and a training culture grounded in probabilistic decision-making. Yass’s firm is influential across derivatives markets even though it is less of a traditional long-only stock-picking franchise.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$4.05B |
| 2 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$1.61B |
| 3 |
Tesla
TSLA
|
+$636M |
| 4 |
TSMC
TSM
|
+$604M |
| 5 |
iShares Bitcoin Trust
IBIT
|
+$330M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Invesco QQQ Trust
QQQ
|
+$1.25B |
| 2 |
Apple
AAPL
|
+$1.13B |
| 3 |
Microsoft
MSFT
|
+$988M |
| 4 |
Meta Platforms (Facebook)
META
|
+$572M |
| 5 |
Berkshire Hathaway Class B
BRK.B
|
+$570M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 94.1% |
| 2 | Technology | 1.55% |
| 3 | Consumer Discretionary | 0.95% |
| 4 | Financials | 0.77% |
| 5 | Healthcare | 0.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
LAR
11751
CALL
Lithium Argentina AG
LAR
$1.13B
| $68.1K | ﹤0.01% |
+31,800
| New | +$80.2K |
|
11752
Gilat Satellite Networks
GILT
$798M
| $68K | ﹤0.01% |
10,715
-22,241
| -67% | -$155K |
|
11753
PUT
T-Rex 2X Inverse NVIDIA Daily Target ETF
NVDQ
$17.3M
| $67.9K | ﹤0.01% |
+900
| New | +$57.5K |
|
|
GAU
11754
Galiano Gold
GAU
$630M
| $67.8K | ﹤0.01% |
54,711
-34,317
| -39% | -$42.2K |
|
|
OCFT
11755
CALL
DELISTED
OneConnect Financial Technology
OCFT
| $67.7K | ﹤0.01% |
+10,100
| New | +$44.7K |
|
11756
Fractyl Health
GUTS
$118M
| $67.5K | ﹤0.01% |
56,694
+14,320
| +34% | +$22.9K |
|
11757
Astrotech Corp
ASTC
$15M
| $67.1K | ﹤0.01% |
+10,355
| New | +$68.5K |
|
11758
TScan Therapeutics
TCRX
$50.8M
| $67.1K | ﹤0.01% |
48,603
+22,768
| +88% | +$49.2K |
|
11759
Sutro Biopharma
STRO
$353M
| $66.6K | ﹤0.01% |
10,234
+2,887
| +39% | +$45.5K |
|
11760
Kyverna Therapeutics
KYTX
$534M
| $66.5K | ﹤0.01% |
34,453
+21,880
| +174% | +$64.7K |
|
11761
Flux Power
FLUX
$13.6M
| $66.4K | ﹤0.01% |
38,595
-56,352
| -59% | -$93.2K |
|
11762
Xenetic Biosciences
XBIO
$9.3M
| $66.3K | ﹤0.01% |
25,388
+9,529
| +60% | +$37.3K |
|
11763
CALL
Playtika
PLTK
$877M
| $66.2K | ﹤0.01% |
12,800
+900
| +8% | +$5.64K |
|
|
CODX
11764
Co-Diagnostics
CODX
$8.8M
| $66K | ﹤0.01% |
7,111
-1,527
| -18% | -$29.2K |
|
|
SIFY
11765
PUT
Sify Technologies
SIFY
$1.07B
| $65.9K | ﹤0.01% |
+15,400
| New | +$61.4K |
|
11766
PUT
Ocugen
OCGN
$465M
| $65.7K | ﹤0.01% |
92,600
-23,500
| -20% | -$16.3K |
|
11767
LiveOne
LVO
$54.3M
| $65.6K | ﹤0.01% |
9,387
+3,075
| +49% | +$30.3K |
|
|
HLVX
11768
DELISTED
HilleVax
HLVX
| $65.4K | ﹤0.01% |
45,132
+31,298
| +226% | +$57.8K |
|
|
UBX
11769
DELISTED
Unity Biotechnology
UBX
| $65.2K | ﹤0.01% |
62,736
+44,046
| +236% | +$79.6K |
|
|
ESPR
11770
CALL
DELISTED
Esperion Therapeutics
ESPR
| $65.2K | ﹤0.01% |
45,300
-179,200
| -80% | -$330K |
|
11771
CALL
Stereotaxis
STXS
$147M
| $65.1K | ﹤0.01% |
37,000
-98,200
| -73% | -$209K |
|
11772
CALL
Skye Bioscience
SKYE
$8.63M
| $64.9K | ﹤0.01% |
+5,100
| New | +$111K |
|
11773
PUT
Everspin Technologies
MRAM
$425M
| $64.8K | ﹤0.01% |
+12,700
| New | +$73.6K |
|
11774
ImmuCell
ICCC
$91M
| $64.7K | ﹤0.01% |
13,501
+1,897
| +16% | +$9.74K |
|
11775
CALL
Solid Power
SLDP
$543M
| $64.4K | ﹤0.01% |
61,300
-13,200
| -18% | -$18.1K |
|
Similar funds
Jeff Yass's Q1 2025 Portfolio in Review
As of Q1 2025, Jeff Yass held 13,842 positions worth $586B, down 12% from $663B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Jeff Yass's Q1 2025 filing shows 1,775 new, 5,712 increased, 4,842 reduced and 1,482 closed positions. Its largest new stake was Brookfield Asset Management: 1,775,684 shares worth $86M. The largest sale was Invesco QQQ Trust, an estimated $1.25B.
By sector, the portfolio is most concentrated in Miscellaneous at 94% of assets, up from 93% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jeff Yass's largest Q1 2025 buy was Brookfield Asset Management: 1,775,684 shares worth $86M.
- Jeff Yass added most to State Street SPDR S&P 500 ETF Trust in Q1 2025, an estimated $4.05B increase.
- Jeff Yass's biggest Q1 2025 reduction was Invesco QQQ Trust, cutting an estimated $1.25B.
- Jeff Yass fully exited Inari Medical, Inc. Common Stock in Q1 2025, selling an estimated $24M.
- Jeff Yass's ten largest holdings make up 28% of its $586B portfolio in Q1 2025.
- Jeff Yass opened 1,775 new positions and closed 1,482 in Q1 2025.
- Jeff Yass's portfolio value fell 12% quarter-over-quarter to $586B.
Based on Susquehanna International Group's 13F filing for Q1 2025, filed 14 May 2025.